Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

NCT03829410 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer
KRAS Gene Mutation

Interventions

DRUG: Onvansertib
BIOLOGICAL: Bevacizumab
DRUG: FOLFIRI

Sponsor

Cardiff Oncology